First Patient Enrolled in Mallinckrodt's Phase 2 Duchenne Muscular Dystrophy Trial | DuchenneXchange

welcome to DuchenneXchange

- a positively charged Duchenne muscular dystrophy community.
  • join today!

First Patient Enrolled in Mallinckrodt’s Phase 2 Duchenne Muscular Dystrophy Trial


Mallinckrodt plc, a leading global specialty pharmaceutical company, today confirmed enrollment of the first patient in the company’s Phase 2 study assessing the efficacy and safety of investigational drug MNK-1411 (cosyntropin, also known as tetracosactide) in patients ages four to eight with Duchenne Muscular Dystrophy (DMD).

Study details, recruiting and contact information

 

https://www.duchennexchange.org/wp-content/uploads/2018/08/1.jpeg